Trinity Biotech soars on glucose monitoring sensor trial data

Trinity Biotech

12/08/2025 18:45

** Shares of biotech firm Trinity Biotech TRIB.O rise 30% to $1.08

** Co says its redesigned needle-free sensor provides accurate glucose readings for 15 days with no finger-stick calibration

** Design modifications, refined signal processing and proprietary sensor operation improvements eliminated the need for calibration, co says

** The continuous glucose monitoring market is forecast to grow from about $13 billion in 2025 to about $28 billion by 2030 - Trinity

** Including session's moves, stock up 20% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))